Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2008 Results
Date:10/30/2008

ROCKVILLE, Md., Oct. 30 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2008.

Vanda reported research and development (R&D) expenses in the third quarter of 2008 of $3.8 million, compared to $5.5 million in the second quarter of 2008 and $13.9 million in the third quarter of 2007. The decrease in R&D expenses in the third quarter of 2008 relative to the second quarter of 2008 is primarily attributable to lower costs in the Phase III tasimelteon (VEC-162) chronic primary insomnia clinical trial for which Vanda announced top-line results in June of 2008. The decrease in R&D expenses in the third quarter of 2008 relative to the third quarter of 2007 is attributable to lower clinical trial costs in 2008 compared to costs from trials conducted in 2007, and the $5.0 million milestone charge recorded in the third quarter of 2007 resulting from the submission of the New Drug Application (NDA) for iloperidone.

Net loss was $10.9 million for the third quarter of 2008, compared to $13.5 million for the second quarter of 2008 and $21.9 million for the third quarter of 2007. Net loss per common share for the third quarter of 2008 was $0.41, compared to $0.51 for the second quarter of 2008 and $0.82 for the third quarter of 2007.

As of September 30, 2008, Vanda's cash, cash equivalents, and marketable securities totaled approximately $51.7 million. As of September 30, 2008, Vanda had a total of approximately 26.7 million shares of common stock outstanding.

OPERATIO
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 Genera Energy Inc. ... innovation and supply chain advancements, has announced the ... Energy Grange™ and Supply ASSURE™. Both systems ... testing aimed at consolidating and simplifying the entire ... farmers and feedstock end users. , “Through the ...
(Date:7/29/2014)... 29, 2014 Quorum Review IRB, ... been awarded accreditation by the International Association ... Lean Six Sigma Deployment Program. The citation recognizes ... performance. , Quorum’s Lean Six Sigma program was ... Program designation. The designation is a public statement ...
(Date:7/29/2014)... Aromas, California (PRWEB) July 29, 2014 ... Droidles is a next generation approach to robotics. What ... toys is patent pending technology that allows them to ... programs, all wirelessly over the internet. , “The invention ... "We're giving the little Droidles a life of their ...
(Date:7/29/2014)... Wendel – recipient of a Regional Top Doctor Award for ... Surgeon Specialists for Nashville, TN – has released a new ... Hydration Booster, Retexturing Night Crème, and Anti-aging C Complex, all ... radiant appearance while protecting them from the sun’s harmful UV ... Dr. J. J. Wendel Plastic Surgery, we have developed a ...
Breaking Biology Technology:Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2Dr. J. J. Wendel Launches New Line of Skin Care Products 2
... , AUSTIN, Texas, July 27 Patton ... of injection port therapy, announced today that they have entered into ... medical devices used in the treatment of diabetes. , , ... The two companies are working together to design and develop the ...
... SAN DIEGO, July 24 Orexigen Therapeutics, Inc. (Nasdaq: ... exercised their overallotment option to purchase an additional 1,500,000 shares ... public offering that priced on July 23, 2009. Including ... a public offering price of $7.50 per share, resulting in ...
... , , , ... , NES-ZIONA, Israel, July 24 PROLOR Biotech, Inc. (OTC Bulletin ... purchase agreements with private investors to sell up to $10 million of the ... per share. As part of the agreements, the company closed on the ...
Cached Biology Technology:Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections 2Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections 3Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters 2PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 2PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 3PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 4
(Date:7/29/2014)... PARIS, 29 JULY 2014 With thirty days to ... for the FEBS-EMBO 2014 Conference are well underway. The ... Biochemical Societies (FEBS), EMBO, and the French Society for ... Saturday, 30 August to Thursday, 4 September at the ... 2014 Conference is the largest meeting for the life ...
(Date:7/29/2014)... study from UC San Francisco is the first to ... overtime and accelerate cellular aging, these negative effects may ... sleeping well. , "The study participants who exercised, ... than the ones who didn,t maintain healthy lifestyles, even ... author Eli Puterman, PhD, assistant professor in the department ...
(Date:7/28/2014)... people in the United States have a circulatory problem ... be painful and may even require surgery in serious ... wasting and, in turn, limb amputation. , At The ... Medical School, scientists tested a non-surgical preventative treatment in ... associated with increased blood circulation. Their proof-of-concept study ...
Breaking Biology News(10 mins):Counting down to FEBS-EMBO 2014 in Paris, France 2Healthy lifestyle may buffer against stress-related cell aging, study says 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... 2010 UT Southwestern Medical Center researchers have found new ... susceptible to stress than others. In a study of ... event, animals that were more susceptible to stress exhibited enhanced ... brain. Specifically, the cells that these animals produced after a ...
... Hemophilia, a disease linked with legends of European monarchs, frail ... people today. And the very treatments that can help ... treatment is infusion with an expensively produced protein that helps ... system fights the therapy, and in a subset of those, ...
... N.J. ―The Center for Secure and Resilient Maritime Commerce (CSR) ... report. Stevens was named by the US Department ... Centers of Excellence and was selected to lead a national ... 11 universities to partner with the DHS and serve as ...
Cached Biology News:New brain nerve cells key to stress resilience, UT Southwestern researchers find 2New brain nerve cells key to stress resilience, UT Southwestern researchers find 3Researchers harness the power of plants to fight hemophilia 2Researchers harness the power of plants to fight hemophilia 3Researchers harness the power of plants to fight hemophilia 4
WIF-1 (N-20)...
... Strong reactivity with rat (100%), ... guinea pig (48%). Slight ... Specificity confirmed by Western blot ... rat Gia-1, Gia-2, rat Gia-3, ...
VEGF Receptor-2, phospho-specific (Tyr996)...
IgG2b, k APC clone A95-1, Isotype Rat IgG2b, kappa, 0.1 mg ....
Biology Products: